138 related articles for article (PubMed ID: 29845459)
21. Dermal, subdermal, and systemic concentrations of granisetron by iontophoretic delivery.
Chaturvedula A; Joshi DP; Anderson C; Morris R; Sembrowich WL; Banga AK
Pharm Res; 2005 Aug; 22(8):1313-9. PubMed ID: 16078141
[TBL] [Abstract][Full Text] [Related]
22. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride.
Wu G; Powers D; Yeung S; Chen F; Neelon K
Int J Pharm Compd; 2018; 22(1):86-94. PubMed ID: 29385389
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of a sublingual film of the antiemetic granisetron hydrochloride.
Kalia V; Garg T; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):842-6. PubMed ID: 25435408
[TBL] [Abstract][Full Text] [Related]
24. [Granisetron versus granisetron plus methylprednisolone in the prevention of chemotherapy induced nausea and vomiting--in adjuvant chemotherapy, including CDDP against gastric cancer].
Kurita A; Takashima S; Nakata M; Kubo Y; Saiki T; Ohsumi S; Yokoyama N; Tanada M; Takiyama W; Saeki H
Gan To Kagaku Ryoho; 1997 Jan; 24(1):49-54. PubMed ID: 9020945
[TBL] [Abstract][Full Text] [Related]
25. Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies.
Cázares-Delgadillo J; Ganem-Rondero A; Quintanar-Guerrero D; López-Castellano AC; Merino V; Kalia YN
Eur J Pharm Sci; 2010 Mar; 39(5):387-93. PubMed ID: 20096354
[TBL] [Abstract][Full Text] [Related]
26. Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret.
Marr HE; Davey PT; Boyle EA; Blower PR
Pharmacology; 1994 May; 48(5):283-92. PubMed ID: 8016189
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies.
El-Setouhy DA; Ahmed S; Badawi AA; El-Nabarawi MA; Sallam N
Eur J Pharm Sci; 2015 Aug; 76():48-56. PubMed ID: 25917526
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.
Endo J; Iihara H; Yamada M; Yanase K; Kamiya F; Ito F; Funaguchi N; Ohno Y; Minatoguchi S; Itoh Y
Anticancer Res; 2012 Sep; 32(9):3939-47. PubMed ID: 22993341
[TBL] [Abstract][Full Text] [Related]
29. [A comparative study of the effect of granisetron and a combination of granisetron plus steroids on cancer chemotherapy induced emesis].
Nukariya N; Nakarai I; Kobayashi H; Koizumi W; Komatsu H; Uchiyama T; Yamaguchi T; Taira O; Minato K; Futatsugi K
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1821-9. PubMed ID: 7574816
[TBL] [Abstract][Full Text] [Related]
30. Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability.
Prentice HG
Support Care Cancer; 2003 Aug; 11(8):501-8. PubMed ID: 12845514
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy.
Caritis S; Zhao Y; Chen HJ; Venkataramanan R
Am J Obstet Gynecol; 2016 Jul; 215(1):93.e1-4. PubMed ID: 26812081
[TBL] [Abstract][Full Text] [Related]
32. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
33. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model.
Endo T; Hamaue N; Ihira E; Teramoto Y; Liu Y; Hirafuji M; Minami M
Res Commun Mol Pathol Pharmacol; 2002; 111(1-4):55-68. PubMed ID: 14632314
[TBL] [Abstract][Full Text] [Related]
34. About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing.
Lehoczky O
Neoplasma; 1999; 46(2):73-9. PubMed ID: 10466429
[TBL] [Abstract][Full Text] [Related]
35. [Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone].
Tanaka K; Sekine M; Serikawa T; Sanada H; Shichiri K; Fujimori R
Gan To Kagaku Ryoho; 1998 May; 25(6):907-13. PubMed ID: 9617330
[TBL] [Abstract][Full Text] [Related]
36. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
[TBL] [Abstract][Full Text] [Related]
37. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy.
Friedman CJ; Burris HA; Yocom K; Blackburn LM; Gruben D
Oncologist; 2000; 5(2):136-43. PubMed ID: 10794804
[TBL] [Abstract][Full Text] [Related]
38. Effects of granisetron with doxorubicin or epirubicin on ECG intervals.
Jantunen IT; Kataja VV; Muhonen TT; Parviainen T
Cancer Chemother Pharmacol; 1996; 37(5):502-4. PubMed ID: 8599877
[TBL] [Abstract][Full Text] [Related]
39. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.
Carmichael J; Bessell EM; Harris AL; Hutcheon AW; Dawes PJ; Daniels S; Bessel EM
Br J Cancer; 1994 Dec; 70(6):1161-4. PubMed ID: 7981069
[TBL] [Abstract][Full Text] [Related]
40. Birefringent physical gels of N-(4-n-alkyloxybenzoyl)-L-alanine amphiphiles in organic solvents: the role of hydrogen-bonding.
Patra T; Pal A; Dey J
J Colloid Interface Sci; 2010 Apr; 344(1):10-20. PubMed ID: 20097349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
